64 results
8-K
EX-99.1
CHRS
Coherus Biosciences Inc
9 May 24
Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
4:17pm
in computing basic and diluted net loss per share
In the quarter ended March 31, 2023, stock-based compensation of $1.0 million was classified within Restructuring charges related to reduction in workforce.
8-K
EX-99.1
pkbgxgxjdso 48lab97
13 Mar 24
Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update
4:16pm
8-K
EX-2.1
rb95q f45
22 Jan 24
Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in Conference Call Information
8:01am
8-K
EX-99.1
s09p5
6 Nov 23
Coherus BioSciences Reports Third Quarter 2023 Financial Results and Business Highlights
4:31pm
8-K/A
EX-99.1
swf4 t76gl50
6 Nov 23
Report of Independent Registered Public Accounting Firm
6:07am
8-K
EX-99.1
llu56erfmr
2 Aug 23
Coherus BioSciences Reports Second Quarter 2023 Financial Results and Business Highlights
4:05pm
425
gbg3jwlp2laxwx7ej1
16 Jun 23
Business combination disclosure
8:08am
425
xr6pcxckhls9eqv
16 Jun 23
Business combination disclosure
7:09am
8-K
EX-2.1
f28000j9nd8ev
16 Jun 23
Coherus to Acquire Surface Oncology
7:06am
8-K
EX-99.1
fc75flb8
8 May 23
Coherus BioSciences Reports First Quarter 2023 Financial Results and Business Highlights
4:16pm